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the risk of stroke in patients with AF, but also 
increase the rate of bleeding.1 To use OAC most 
effectively at the lowest risk, patients must be 
fully compliant. The attending physicians who 
diagnose AF and initiate OAC therapy serve as a 
INTRODUCTION Atrial fibrillation (AF) is a 
chronic condition that requires lifelong antico-
agulation in most patients. Oral anticoagulants 
(OACs), both vitamin K antagonists (VKAs) and 
non-VKA oral anticoagulants (NOACs), diminish 
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ABSTRACT
BACKGROUND The Jessa Atrial Fibrillation Knowledge Questionnaire (JAKQ) was successfully used to 
assess knowledge gaps in patients with atrial fibrillation (AF).
AIMS To evaluate the regional differences among Polish patients in their awareness of AF diagnosis and 
oral anticoagulation use.
METHODS A total of 1583 patients with AF at a median (IQR) age of 72 (66–79) years completed the JAKQ 
in 3 cardiology centers (center I, Kraków; center II, Toruń; center III, Kielce) from January 2017 to June 
2018. The final analysis included 1525 patients, 32.9% were on vitamin K antagonists (VKAs) and 67.1% 
on non-VKA oral anticoagulants (NOACs), that is, rivaroxaban and dabigatran (28.9% each), and apixaban 
(9.3%).
RESULTS The mean (SD) score on the JAKQ was 55.5% (18.4%) with better results among patients on 
VKAs compared with NOACs (58% [18.3%] vs 54.3% [18.4%]; P = 0.0002) with time from AF diagnosis more 
than 12 months (57.4% [17.5%] vs 50% [19.9%]; P <0.0001). There was a significant difference in the 
knowledge scores between the 3 centers (I, 59.5%; II, 48.5%; III, 54.3%; P <0.0001). In all centers the 
number of correct answers correlated inversely with patient’s age (r = –0.20; P <0.0001). NOACs were 
more frequently used in center III. The percentage of correct responses was lower in patients on reduced 
NOAC doses (35.4% of patients on NOACs), compared with the full-dose NOAC groups in center I (56.9% 
vs 62.5%; P = 0.012) and II (48.1% vs 56.2%; P = 0.003).
CONCLUSIONS Patients from a high-volume academic center showed better knowledge than their peers 
from district hospitals. There are large regional differences in prescription patterns of oral anticoagulants, 
including the preferred NOAC.
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center with 3 university departments, 1 cardi-
ology ward (105 544 hospitalized patients in 
2017), and 36 742 outpatients. Center II (Car-
diology Ward, District Hospital in Toruń) had 
3200 inpatients and 5650 outpatients in 2017. 
Center III (the Świętokrzyskie Cardiology Cen-
tre in Kielce) had 7602 inpatients and 9278 out-
patients in 2017.
Patients participating in the study were older 
than age 18 years and were able to provide con-
sent. The questionnaire was completed in the 
presence of a physician.
The questionnaire The JAKQ was used af-
ter obtaining formal consent from Hasselt Uni-
versity, Belgium. The questionnaire consists of 
16 multiple choice questions with 1 correct an-
swer, which was previously described in detail 
by Konieczyńska et al.8 The detailed summary 
is available in the Supplementary material. The 
final analysis included in this article conformed 
to the original JAKQ analysis by Desteghe et al4 
and to the analysis by Konieczyńska et al.8 If a 
patient provided 2 or more responses despite 
clear instructions, the response was assessed 
as incorrect. Doctors who collected the ques-
tionnaires completed clinical data about OAC, 
its dose, time of treatment, time of diagnosis, 
comorbidities, antiplatelet use, and prior severe 
bleeding or cerebrovascular ischemic events. Co-
morbidities were defined as presented in Sup-
plementary material. Bleeding severity was de-
fined according to the International Society of 
Thrombosis and Haemostasis.9
Statistical analysis The total score was pre-
sented as the percentage of correct answers. Cat-
egorical data were presented as numbers and per-
centages. The χ2 test or Fisher exact test were 
used to compare proportions. Numerical vari-
ables were presented as mean and SD or medi-
an and interquartile range (IQR), as appropri-
ate, and compared by the t test, 1-way analysis 
of variance (ANOVA), Mann–Whitney test, or 
Kruskal–Wallis test, as appropriate. The rela-
tionship between the number of correct answers 
and age as well as between time since AF onset 
and time since OAC initiation was assessed by 
the Spearman rank correlation coefficient. A 
P value below 0.05 was considered statistical-
ly significant. All statistical analyses were per-
formed using the R statistical software (version 
3.1.2; The R Foundation for Statistical Comput-
ing, Vienna, Austria).
RESULTS Patient characteristics A total of 
1583 patients completed the questionnaire. The 
answers of 28 individuals (1.8%) were excluded 
because low-molecular-weight heparin was used 
as an anticoagulant, and 30 (1.9%) because data 
were missing. The final analysis encompassed 
primary source of knowledge for their patients. 
However, it is important to repeatedly reevaluate 
the information about the disease and its treat-
ment that is still lacking and needs to be repeat-
ed and emphasized.2-6 Current guidelines empha-
size the role of education in the efficacy and safe-
ty of OAC therapy.1,7 So far, a few questionnaires 
have been published as useful tools for assess-
ing knowledge of patients with AF.5,6 One of such 
tools is the Jessa AF Knowledge Questionnaire 
(JAKQ), designed and validated by researchers 
from Hasselt University in Belgium.4 In 2016 
they demonstrated important gaps in patients’ 
knowledge regarding AF and OAC therapy. De-
steghe et al5 also proved that the JAKQ is an ef-
ficient tool in patients’ education that can help 
to improve the awareness of AF and its manage-
ment. The use of the JAKQ in a Polish population 
has been reported by Konieczyńska et al,8 who 
studied 479 patients with AF on OACs, includ-
ing 276 patients (57.6%) receiving NOACs. The 
level of patient knowledge was similar to that 
reported by Desteghe et al.4 Scores in the VKA 
and NOAC groups did not differ significantly in 
Polish patients (61.6% vs 60.7%, respectively; P 
= 0.4). The study showed the current anticoagu-
lation trends in Poland, presenting rivaroxaban 
(51.7%) as the most commonly used NOAC. Re-
duced doses were administered to 33%, 37.7%, 
and 60% of patients receiving rivaroxaban, dab-
igatran, and apixaban, respectively. However, 
it was a single-center study performed in a ter-
tiary high-volume center with an anticoagula-
tion clinic.
The aim of the present study was to evaluate 
the regional differences in patient awareness 
considering AF diagnosis and OAC use, to iden-
tify factors influencing their knowledge, and to 
assess the anticoagulation patterns in 3 cardi-
ology centers in Poland.
METHODS Patients Patients with document-
ed AF who were receiving oral anticoagulation 
were recruited in 3 different cardiology cen-
ters both from in- and outpatient clinics from 
January 2017 to June 2018. Center I, the John 
Paul II Hospital in Kraków, is a tertiary care 
WHAT’S NEW?
Considerable differences in the prescription patterns of oral anticoagulants, 
including vitamin K antagonists and non–vitamin K antagonist oral 
anticoagulants, and in knowledge of atrial fibrillation were observed in large 
cardiology departments of 3 Polish cities, Kraków, Toruń, and Kielce. The Jessa 
Atrial Fibrillation Knowledge Questionnaire was used for the assessment. These 
differences may impact the effectiveness and safety of oral anticoagulant 
therapy and may help to set regional educational aims for specific atrial 
fibrillation populations. Further efforts are needed to improve knowledge 
about atrial fibrillation and its anticoagulant therapy in Poland and in other 
countries.
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scores were achieved by patients with prior myo-
cardial infarction as compared with those with-
out prior myocardial infarction (52.7% [18.2%] 
and 56.3% [18.2%] respectively; P = 0.001). The 
same was true for diabetic patients as compared 
with those without this disease (54% [19%] and 
56.% [18.1%], respectively; P = 0.033), and pa-
tients with heart failure as compared with those 
without heart failure (54.2% [19.5%] and 56.5% 
[18.3%], respectively; P = 0.019), with a similar 
prevalence of these diseases in most patients. 
Three questions with the highest percentage of 
correct responses were those regarding the in-
dication for OAC (84.4%), related to the recom-
mended frequency of measurement of interna-
tional normalized ratio (90.6%), and concerning 
the importance of fixed hours of taking NOAC 
(90.4%). Poor patient knowledge was observed in 
the topics of the effectiveness of antiarrhythmic 
drugs (31% of correct answers) and procedures 
in case of anticoagulant dose omission (VKA 
group, 24.1%; NOAC group, 38.4%).
The worst scores were achieved by patients 
from center II (I, 59.5%; II, 48.5%; III, 54.3%; 
P <0.0001; FIGURE 1). The following topics were as-
sociated with a similar number of correct re-
sponses in all 3 centers: the importance of a 
regular anticoagulant intake despite the lack of 
symptoms, frequency of international normal-
ized ratio measurements, and taking NOAC at 
fixed hours. Patients from center III were more 
aware that overweight exacerbates AF (I, 53.1%; 
II 53.6%; III, 62.4%; P = 0.003) and more familar 
with the procedure in case of omitting a dose of 
VKA (I, 21.4%; II, 17.8%; III, 33.6%; P = 0.007). 
Patients from center II had the lowest number 
of correct answers regarding lack of symptoms 
in AF (I, 35.0%; II, 22.1%; III, 39.8%; P <0.0001) 
and the need to consult their physician before 
planned surgery while on OAC (I, 72.5%; II, 
65.7%; III, 74.7%; P = 0.019).
Weak positive correlations were observed be-
tween the number of correct answers and the 
time from AF onset (r = 0.13; P <0.0002) and 
from OAC initiation (r = 0.18; P <0.0003). There 
was an inverse association between the num-
ber of correct answers and the patient’s age 
(r = –0.20; P <0.0001) in the whole group. Simi-
lar observations were made for participating cen-
ters; however, there was no correlation between 
the knowledge score and the time from AF on-
set in center I (I, r = 0.05; P = 0,18; II, r = 0.14; P 
= 0.009; III, r = 0.19; P = 0.000017).
Knowledge on vitamin K antagonists com-
pared with non–vitamin K antagonist oral 
anticoagulants In the whole study group, pa-
tients on NOACs more often had paroxysmal AF 
and shorter time from AF diagnosis and OAC ini-
tiation. They less frequently had heart failure, 
diabetes, and mitral stenosis. The incidence of 
antiplatelet drug use and major bleedings was 
1525 patients (96.3%), including 585 outpatients 
(38.4%) and 940 hospitalized patients (61.6%). 
Age of the patients ranged from 22 to 96 years 
(median [IQR], 72 [66–79]). Women represent-
ed 45.5% of the study population. Paroxysmal 
and permanent AF were the most common types 
of the disease (43.7% and 39.5%, respective-
ly). The median (IQR) time from AF diagnosis 
was 48 (12–108) months and median (IQR) an-
ticoagulation duration was 18 (5–48) months. 
The majority of the patients (67.1%) were treat-
ed with NOACs, that is, rivaroxaban and dabi-
gatran (28.9% each), and apixaban (9.3%), and 
one-third received warfarin or acenocoumarol 
(32.9%). Concomitant antiplatelet therapy was 
identified in 22.3% of patients (aspirin, 15% and 
clopidogrel, 7.3%).
Comparison of the 3 centers The youngest 
patients came from center I, and the oldest from 
center II (TABLE 1). Center II had more patients with 
persistent AF, a shorter time since the onset of 
AF, and the shortest anticoagulation duration 
compared with the other centers. NOAC use was 
reported more frequently in center III. Rivar-
oxaban was administered more often in center 
II (48.1%), and dabigatran in center III (54.6%). 
Center I prescribed rivaroxaban (47.1%) and dab-
igatran (41.8%) at similar rates. Among patients 
treated with NOAC at reduced doses, 15 mg/d of 
rivaroxaban was most commonly used in centers 
I and II. Patients from center I suffered more 
commonly from arterial hypertension, diabe-
tes, and vascular disease. Prior stroke or tran-
sient ischemic attack was observed more often 
in centers I and III, while patients with prior 
myocardial infarction were overrepresented in 
center II (TABLE 1).
The mean (SD) score on the JAKQ was 55.5% 
(18.4%) with no significant difference between 
men and women (54.8% [18.1%] and 56.3% 
[18.8%], respectively; P = 0.13). Better results 
were obtained in patients under the age of 75 
years as compared with those older than 75 
years of age (58.1% [17.2%] and 50.8% [19.7%], 
respectively; P <0.0001), treated with VKAs 
as compared with those treated with NOACs 
(58% [18.3%] and 54.3% [18.4%], respectively; 
P = 0.0002), with more than 12 months since 
the AF diagnosis as compared with those with 
less than 12 months (57.4% [17.5%] and 50% 
[19.9%], respectively; P <0.0001), with anticoag-
ulation duration over 1 year as compared with 
those with anticoagulation duration of less than 
1 year (58.3% [17.6%] and 52.1% [18.9%], respec-
tively; P <0.0001). Patients receiving clopidogrel 
as compared with those not receiving this drug 
(48.9% [19%] and 56% [18.3%], respectively; P = 
0.0002) had results almost identical to those di-
agnosed with vascular disease as compared with 
those without vascular disease (52% [19%] and 
56.5% [18.2%], respectively, P <0.0001). Lower 
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TABLE 1 Patient characteristics
Variable Center I  
(n = 702)
Center II  
(n = 321)
Center III 
(n = 502)
P value
Demographic data
Age, y, median (IQR) 70 (64–78) 74 (66–80) 72 (65–79) 0.0003
Female sex 327 (46.6) 132 (41.1) 233 (46.4) 0.23
AF type
Paroxysmal 314 (44.7) 121 (37.7) 232 (46.2) <0.0001
Persistent 111 (15.8) 94 (29.3) 44 (8.8)
Permanent 271 (38.6) 106 (33) 226 (45)
Unknown 6 (0.9) 0 (0) 0 (0)
Time since AF onset, mo, median (IQR) 48 (18–96) 30 (7–96) 48 (12–120) 0.0004
Time since OAC initiation, mo, median (IQR) 22 (8–48) 8 (2–28) 18 (4–47.5) <0.0001
OAC type
NOAC 450 (64.1) 214 (66.7) 359 (71.5) 0.025
Rivaroxaban 20 mg once daily 145 (20.7) 64 (19.9) 90 (17.9) 0.49
Rivaroxaban 15 mg once daily 70 (10) 39 (12.1) 33 (6.6) 0.017
Dabigatran 150 mg twice daily 125 (17.8) 33 (10.3) 125 (24.9) <0.0001
Dabigatran 110 mg twice daily 63 (9) 23 (7.2) 71 (14.1) 0.002
Apixaban 5 mg twice daily 21 (3) 37 (11.5) 21 (4.2) <0.0001
Apixaban 2.5 mg twice daily 26 (3.7) 18 (5.6) 19 (3.8) 0.34
VKA 252 (35.9) 107 (33.3) 143 (28.5) 0.025
Acenocoumarol 133 (18.9) 53 (16.5) 89 (17.7) 0.64
Warfarin 119 (17) 54 (16.8) 54 (10.8) 0.005
Antiplatelet therapy
Aspirin 123 (17.5) 66 (20.6) 39 (7.8) <0.0001
Clopidogrel 32 (4.6) 58 (18.1) 21 (4.2) <0.0001
Comorbidities
Heart failure 283 (40.3) 143 (44.5) 226 (45) 0.20
Arterial hypertension 601 (85.6) 257 (80.1) 399 (79.5) 0.009
Diabetes 250 (35.6) 95 (29.6) 141 (28.1) 0.014
Prosthetic valve 53 (7.5) 20 (6.2) 44 (8.8) 0.43
Mitral stenosis 23 (3.3) 7 (2.2) 15 (3) 0.68
Prior myocardial infarction 151 (21.5) 99 (30.8) 113 (22.5) 0.004
Vascular disease 215 (30.6) 36 (11.2) 85 (16.9) <0.0001
Prior major bleeding 80 (11.4) 19 (5.9) 48 (9.6) 0.019
VKA in the past 143 (20.4) 62 (19.3) 112 (22.3) 0.56
Data are presented as numbers and percentages unless otherwise stated.
Abbreviations: AF, atrial fibrillation; IQR, interquartile range; NOAC, non–vitamin K antagonist oral anticoagulant; OAC, oral 
anticoagulant; VKA, vitamin K antagonist
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FIGURE 1  
Distribution of correct 
responses in patients 
treated with non–vitamin K 
antagonist oral 
anticoagulants and vitamin 
K antagonists
TABLE 2  Comparison of patients with atrial fibrillation treated with non–vitamin K antagonist oral anticoagulants and vitamin K antagonists
Variable NOAC (n = 1023) VKA (n = 502) P value
Demographic data
Age, y, median (IQR) 71 (64–79) 72 (66–79) 0.18
Female sex 481 (47) 211 (42) 0.07
AF type
Paroxysmal 503 (49.2) 164 (32.7) <0.0001
Persistent 215 (21.0) 34 (6.8)
Permanent 302 (29.5) 301 (60.0)
Unknown 3 (0.3) 3 (0.6)
History of AF and anticoagulation
Time since AF onset, mo, median (IQR) 27 (10–60) 96 (40–156) <0.0001
Time since OAC initiation, mo, median (IQR) 11 (3–24) 60.0 (24–120) <0.0001
Antiplatelet therapy
Aspirin 157 (15.3) 71 (14.1) 0.59
Clopidogrel 81 (7.9) 30 (6.0) 0.21
Comorbidities
Heart failure 378 (37.0) 274 (54.6) <0.0001
Arterial hypertension 841 (82.2) 416 (82.9) 0.77
Diabetes 303 (29.6) 183 (36.5) 0.008
Prosthetic valve 8 (0.8) 109 (21.7) <0.0001
Mitral stenosis 16 (1.6) 29 (5.8) <0.0001
Prior myocardial infarction 233 (22.8) 130 (25.9) 0.18
Vascular disease 206 (20.1) 130 (25.9) 0.012
VKA in the past 317 (31.0) – –
Data are presented as numbers and percentages unless otherwise stated.
Abbreviations: see TABLE 1
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on apixaban, as compared with patients on ri-
varoxaban and dabigatran, received antiplatelet 
agents more frequently (aspirin, 38.2%, 13.6%, 
and 17.9%, respectively; P = 0.002; clopidogrel, 
40.4%, 14.3%, and 8.7%, respectively; P <0.0001).
There was no age difference in center III 
among patients taking different NOACs. Pa-
tients treated with apixaban, compared with 
those on rivaroxaban and dabigatran, more often 
received aspirin (20%, 6.5%, and 8.7%, respec-
tively; P = 0.04) and had prior myocardial infarc-
tion (50%, 14.6%, 21%, respectively; P <0.0001).
The proportion of correct responses in the 
JAKQ was similar in all NOAC groups; however, 
patients treated with rivaroxaban and dabiga-
tran, as compared with those on apixaban, were 
more aware of the necessity of taking their drugs 
irrespectively of AF symptoms (80.3%, 85.7%, 
and 75.4%, respectively; P = 0.01).
Reduced NOAC doses were prescribed to 
35.4% of the patients. Rivaroxaban was used in 
32.2% of the patients, dabigatran in 35.7%, and 
apixaban in 47.7%. Patients receiving reduced 
NOAC doses, as compared with those receiv-
ing full doses, were older (80.0 [74.0–84.0] and 
68 [61.0–73.0] years, respectively; P <0.0001), 
were more often women (52.8% and 43.9%, re-
spectively; P = 0.007), more frequently used 
concomitant antiplatelet drugs (aspirin, 21.3% 
and 12.1%, respectively; P = 0.0001; clopidogrel, 
15.7% and 3.6%, respectively; P <0.0001), and 
more often had history of heart failure (45.9% 
and 32.1%, respectively; P <0.0001), arterial hy-
pertension (85.6% and 80.3%, respectively; P 
= 0.04), and prior myocardial infarction (33.4% 
and 16.9%, respectively; P <0.0001). Patients on 
reduced NOAC doses had less correct responses 
as compared with those on full doses (mean [SD], 
51.5% [18.7%] and 55.7% [18.1%], respectively; 
P = 0.0005), and this difference was mainly ob-
served in center I (56.9% and 62.5%, respective-
ly; P = 0.012) and center II (48.1% and 56.2%, re-
spectively; P = 0.003).
DISCUSSION The present study compared 
knowledge about AF and anticoagulation treat-
ment in a large patient cohort recruited from 3 
Polish cardiology centers in the years 2017 and 
2018. This population was larger than those pre-
viously reported.4,6,8 This report focused on re-
gional differences with regard to the knowledge 
of AF and its management in a single country 
with no reimbursement system for NOAC in 
patients with AF. The present study shows that 
there are huge differences among 3 big cities with 
large cardiology departments, from types of oral 
anticoagulants used in patients with AF, to pa-
tient knowledge on how to use these drugs safe-
ly. These observations may implicate that region-
al educational initiatives should be set in place 
for specific populations of patients with AF to 
similar in both groups (TABLE 2). Those differenc-
es were consistent among all 3 centers (Supple-
mentary Material, Table S1).
Patients on NOACs were more aware of AF 
complications compared with those on VKAs 
(67.4% and 59.4%, respectively; P = 0.002). Pa-
tients on VKAs, as compared with those on NO-
ACs, achieved better scores in questions on the 
management in case of an AF episode (38.4% 
and 28.8%, respectively; P = 0.002) and in ques-
tions regarding the indication for OAC (86.9% 
and 81.9%, respectively; P = 0.015). There were 
no differences in distribution of correct answers 
to the other questions.
In center I, patients on NOACs, compared with 
those on VKAs, had better knowledge of AF self-
detection (52.9% and 44.4%, respectively; P = 
0.034) and possible complications (80.9% and 
67.1%, respectively; P <0.0001). However, pa-
tients receiving VKAs, as compared with those 
receiving NOACs, had a better awareness of the 
adequate self-management in case of an AF epi-
sode (87.3% and 81.1%, respectively; P = 0.035). 
There were no significant differences between 
both treatment groups in center II. Patients re-
ceiving VKAs, as compared with those receiving 
NOACs, in center III were more aware that AF 
is not always accompanied by symptoms (49.7% 
and 35.9% respectively; P <0.0001), were more fa-
miliar with side effects of anticoagulation (55.9% 
and 45.1%; P = 0.03), and the management of 
minor bleedings (77.6% and 67.1%; P = 0.023).
Patients on different non–vitamin K antago-
nist oral anticoagulants In the whole group, 
the proportion of patients on rivaroxaban and 
dabigatran were similar (43.1% and 43.0%, re-
spectively), and the apixaban group was much 
smaller (13.9%). Patients taking apixaban, as 
compared with those on rivaroxaban and dab-
igatran, were the oldest (median [IQR], I, 76 
[68–81]; II, 71 [64–78]; III, 71 [63–78] years; 
P = 0.0002) and received anticoagulant therapy 
for the shortest time (I, 4 [1–10]; II, 14 [6–27]; III, 
11 [3–24] months; P <0.0001). Patients on apixa-
ban more often received concomitant antiplate-
let treatment (aspirin, I, 26.1%; II, 13.4%; III, 
13.9 %; P = 0.001; clopidogrel, I, 20.4%; II, 6.1%; 
III, 5.7%; P <0.0001). More patients on apixaban 
had myocardial infarction in the past (I, 38%; 
II, 19.3%; III, 21.4%; P <0.0001) in comparison 
with the rivaroxaban and dabigatran groups. Pa-
tients on rivaroxaban, compared with those on 
dabigatran and apixaban, had the longest time 
from AF diagnosis (I, 36; II, 24; III, 22 months; 
P = 0.002).
In center I, more women (I, 61.7%; II, 52.6%; 
III, 43.1%; P = 0.035) and patients with prior 
stroke (I, 21.3%; II, 9.8%; III, 16.5%; P = 0.038) re-
ceived apixaban than rivaroxaban or dabigatran.
In center II, age was similar in the 3 groups 
of patients receiving different NOACs. Patients 
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relatives and caregivers. Alarmingly, concomi-
tant aspirin or clopidogrel use was higher than in 
other reports4,6 and associated with lower knowl-
edge scores. As antiplatelet therapy combined 
with OAC significantly increased the bleeding 
risk,11 individualized targeted education about 
the higher bleeding risk should be proposed to 
this subgroup. Patients with prior myocardial in-
farction also gained lower scores on the JAKQ, 
possibly due to the fact that the attention both 
of the patient and physician was directed at sec-
ondary prevention of myocardial infarction, but 
not sufficiently focused at stroke risk associat-
ed with concomitant AF.
We observed better scores in patients with the 
interval from AF onset or the anticoagulation 
duration longer than 12 months. Although their 
associations were weak, this novel finding sug-
gests that the longer the treatment of patients 
with AF, the better their knowledge about the 
disease and drugs used.
In contrast to the previous study with the 
JAKQ in Poland,8 we found that patients on 
VKAs generally achieved better results than 
those on NOACs. A possible explanation for this 
observation could be a longer period between AF 
onset and OAC initiation in patients on VKAs; 
both factors were identified as variables posi-
tively associated with the scores in the JAKQ. 
It indicates that accumulating educational ef-
forts and a larger number of ambulatory visits 
or hospitalizations observed in the case of sev-
eral years of OAC use, improve the knowledge 
about AF and its management. It might be spec-
ulated that with time a similar phenomenon will 
be noted among AF patients receiving NOACs.
Our study yields insights into rapidly chang-
ing trends in anticoagulant therapy in Poland. 
We showed that NOACs were the preferred OACs 
in 2017 and mid-2018. The low prescription rate 
of apixaban in relation to dabigatran and rivar-
oxaban may be attributed to the fact that it was 
introduced to the Polish market in 2014 at a very 
high price. As real-world data indicate that apix-
aban use in patients with AF is related to lower 
bleeding risk,12,13 it is prescribed more often to 
patients with higher bleeding risk (older or on 
antiplatelet therapy). Of note, we found region-
al preferences in prescribing a specific NOAC, 
which are hard to explain looking at the patient 
characteristics, and this might be due to local 
preferences of the attending cardiologists. In 
center I, dabigatran and rivaroxaban were used 
similarly, while rivaroxaban was preferred in 
center II and dabigatran in center III. Interest-
ingly, we observed that one-third of the patients 
receiving NOAC took reduced doses, which is 
consistent with the findings by Konieczyńska et 
al.8 Steinberg et al14 reported reduced NOAC dos-
es in 16% of American patients. In the Europe-
an registry, the Xarelto for Prevention of Stroke 
in Patients with Atrial Fibrillation (XANTUS), 
improve the effectiveness and safety of antico-
agulant therapy. We postulated the development 
and implementation of a national educational 
program based on validated questionnaires and 
directed towards patients who require lifelong 
anticoagulation, including those with recurrent 
venous thromboembolism, as they had similar 
knowledge gaps regarding the use of OAC,10 to 
improve clinical outcomes.
The main novel finding was that patients’ 
knowledge was dependent on the facility type 
they were recruited from. Patients with AF man-
aged in the academic reference center with a ded-
icated anticoagulation clinic scored significantly 
better than their peers from district hospitals. 
It might suggest that, in the era of NOAC anti-
coagulation, clinics pursue educational objec-
tives directed towards patients and physicians.
Our study was conducted from 2017 to mid-
2018. The current real-world population was 
older than in most other studies, with a similar 
percentage of women.4,6,8 The incidence of heart 
failure, diabetes, and hypertension was higher 
than in the European Heart Rhythm Associa-
tion registry,6 which confirms a common view 
that in everyday practice, patients with AF are 
“sicker” than those enrolled in selected leading 
centers or in randomized trials with multiple 
exclusion criteria. Surprisingly, we observed a 
very high rate of NOAC use, similar to that re-
ported by Desteghe et al,4 but significantly high-
er than in other European observational stud-
ies reporting data from 2011 to 2016.6 This ob-
servation indicates that despite the fact that 
NOACs are quite expensive and there is no re-
imbursement of these agents in Poland, advan-
tages of newer anticoagulants are important for 
patients and physicians, including no need for 
routine laboratory monitoring, fixed-dose reg-
imens with predictable anticoagulant effects, 
fewer drug interactions, and no food interac-
tions. On the other hand, our patients came 
from urban areas, where incomes are generally 
higher, and the result may be not representative 
for the entire Polish population. However, the 
highest percentage of NOAC use was in center 
III, which serves as a reference center for a low-
income population in Poland. This study proves 
that the use of NOACs is growing, even among 
patients with limited resources.
Unfortunately, patient general awareness of 
AF and anticoagulation treatment was insuf-
ficient, which is consistent with previous re-
ports.4,6 As expected, older patients with more 
comorbidities achieved worse results. As their 
risk of both stroke and bleeding is higher, this 
observation rises concern about patient safe-
ty and indicates the urgent need for education-
al initiatives. As older age and the presence of 
multiple comorbidities are often accompanied 
by cognitive disorders, the educational pro-
gram should also be directed towards patients’ 
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performed in 2013 and 2014,15 rivaroxaban in 
reduced dose was found in less than 10% of pa-
tients. The use of reduced NOAC doses in our 
study was associated with older age and the con-
comitant use of antiplatelet drugs, which indi-
cates a higher bleeding risk perceived by physi-
cians, despite the fact that the main indication 
for the NOAC dose reduction is renal insufficien-
cy.1 It is unclear if NOAC dosing regimens were 
in accordance with current guidelines since cre-
atinine clearance was not available.
The study has several limitations. It was con-
ducted in large cardiology departments, there-
fore our results could not be easily translat-
ed to primary care in rural regions or in small 
towns. Knowledge levels of patients with AF 
can possibly differ between hospitals even in 
the same large city. We did not analyze the ef-
fect of the level of education or cognitive func-
tion of patients on AF-related knowledge. Our 
study was focused on the patients’ knowledge 
about AF and its treatment and we did not col-
lect the compliance data. Finally, it remains to 
be established whether the scores on the JAKQ 
are related to bleeding or stroke events during 
long-term follow-up.
In conclusion, patient knowledge on AF and 
its treatment is influenced by the type of facili-
ty they are treated at and the facility’s location 
in the same country. Patients from a high-vol-
ume academic center achieved better scores than 
their peers from district hospitals. There are re-
gional preferences in NOAC use. Further efforts 
are needed to improve the effectiveness of AF 
therapy, in part through better education with 
specific goals set regionally.
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